Specialised techniques give a more thorough understanding and provide early insights into how drug products will behave in patients’ hands.
Vectura’s advanced in-house analytical capability cements the company’s ability to support all phases of inhalation product development. Vectura has extensive state-of-the-art analytical testing facilities and equipment, and an expert analytical workforce able to fully develop and validate all methods required to characterise complex inhalation products, not just for small molecules and combinations thereof but also for complex biologic inhalation products.
In addition to analytical methods required to support regulatory submissions for new treatments, we are able to use more specialised techniques that give a more thorough drug product understanding and provide early insights into how drug products will behave in patients’ hands. This is a particular area of focus in developing generics, where we have to demonstrate bioequivalence both in the laboratory and in a clinical setting. Vectura’s expertise in this area sets the company apart from others.